GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Equity-to-Asset

Tourmaline Bio (Tourmaline Bio) Equity-to-Asset : 0.98 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Tourmaline Bio's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $205.04 Mil. Tourmaline Bio's Total Assets for the quarter that ended in Dec. 2023 was $210.30 Mil.

The historical rank and industry rank for Tourmaline Bio's Equity-to-Asset or its related term are showing as below:

TRML' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.17   Med: -1.51   Max: 0.98
Current: 0.98

During the past 3 years, the highest Equity to Asset Ratio of Tourmaline Bio was 0.98. The lowest was -2.17. And the median was -1.51.

TRML's Equity-to-Asset is ranked better than
99.17% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs TRML: 0.98

Tourmaline Bio Equity-to-Asset Historical Data

The historical data trend for Tourmaline Bio's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tourmaline Bio Equity-to-Asset Chart

Tourmaline Bio Annual Data
Trend Dec21 Dec22 Dec23
Equity-to-Asset
-1.51 -2.17 0.98

Tourmaline Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial - -2.17 -0.46 0.95 0.98

Competitive Comparison of Tourmaline Bio's Equity-to-Asset

For the Biotechnology subindustry, Tourmaline Bio's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tourmaline Bio's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tourmaline Bio's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Tourmaline Bio's Equity-to-Asset falls into.


Tourmaline Bio Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Tourmaline Bio's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=205.042/210.295
=

Tourmaline Bio's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=205.042/210.295
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tourmaline Bio  (NAS:TRML) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Tourmaline Bio Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Tourmaline Bio (Tourmaline Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Equity-to-Asset
Comparable Companies
CYTK NUVL KRYS CRSP INSM FOLD BPMC IMGN AXSM ACAD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
27 West 24th Street, Suite 702, New York, NY, USA, 10010
Website
https://www.tourmalinebio.com
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.